logo
Prescription drug costs are forcing Canadians to make dangerous trade-offs

Prescription drug costs are forcing Canadians to make dangerous trade-offs

Globe and Mail7 days ago
Heather Evans, 60, used to eat boxed macaroni and cheese three times a week, but not because she loved it. She had to scrimp on her food budget to afford the thousands of dollars a month for the medication keeping her alive.
Ms. Evans was diagnosed with a chronic heart condition in her 30s. 'I had my first two heart attacks when I was 39. I didn't sleep for almost 10 months because I was afraid I wouldn't wake up, and I didn't want my five-year-old son to find me gone.'
At the time, Ms. Evans was an unemployed single mom in Calgary with no health insurance benefits. Most prescription medications aren't covered under Canada's universal health care plan, meaning patients without extended benefits have to foot the bill. Canada is the only country with universal health care that does not have universal coverage for prescription drugs (outside hospitals).
The cost of survival nearly broke Ms. Evans. 'You go to sleep with tears in your eyes, worried about the next day. If it wasn't for my doctor giving me samples for so many years, I don't know that I'd be here today.'
As millions of Canadians struggle to cope with the cost of their medications, many have taken drastic steps to alleviate the pressure, often leading to a worsening of their symptoms over time.
A 2024 survey by Leger found that nearly one in four Canadians (22 per cent) say they've split pills, skipped doses, or chosen not to fill or renew a prescription because of the cost. The survey also revealed that 1 in 10 Canadians living with chronic conditions have landed in emergency after their health worsened because they couldn't afford the medications they needed.
'There are real downstream impacts. If you can't access drugs for prevention purposes you end up burdening the health care system, and that's much more expensive,' says Manuel Arango, director of Health Policy and Advocacy for the Heart and Stroke Foundation. 'It's way more cost effective to provide these drugs and tear down affordability barriers, so that people can be healthy, manage their conditions and stay out of the emergency rooms.'
Canada has a patchwork of public drug benefit programs (with varying eligibilities), along with many private insurance plans. But insurance coverage, while helpful, isn't a guarantee of affordability. The 2019 Hoskins report about pharmacare implementation found that about 7.5 million Canadians still face high out-of-pocket costs.
Gaps in coverage are made worse by shifting work patterns and employer plans that offload costs onto workers, putting part-time, contract, and low-income workers most at risk.
Canada's proposed national pharmacare plan aims to provide coverage for essential prescription medications. The federal government says the program will roll out in phases, and has already started with coverage for contraceptives and diabetes drugs in British Columbia, Prince Edward Island, Manitoba and Yukon.
The plan's advisory panel recommended covering medications for cardiac conditions, but they remain uncovered.
'We appreciate these initial steps the government has taken, but we need to move more quickly,' says Mr. Arango. 'We need to get on the same playing field as all other countries that have universal health care systems and institute universal drug coverage.'
A recent study from Arthritis Research Canada (ARC) showed that for nearly 1 in 20 people aged 12 or older, cost is a major barrier to taking their medications as prescribed. Some groups face higher risks for non-adherence with prescriptions, including women, members of racialized communities and people with diverse sexual orientations. Each skipped dose has ramifications for patients, says Dr. Mary De Vera, an ARC senior scientist.
'Drugs are health care. So why is it so disjointed?' she says. 'The ideal situation is that we have a system that mirrors our medical system.'
Ms. Evans is now the general manager of a GoodLife gym in Calgary, and has health insurance that covers her medication. Others are not as fortunate. She says she wishes decision-makers would put themselves in the shoes of families forced to choose between paying for food or their prescriptions.
'I want them to think about their own loved ones being in the same situation and tell me they wouldn't move a mountain to make sure they'd be okay. People are dying because they can't afford life-saving medications,' Mr. Evans says. 'It's so unjust and we need to do better.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management

Globe and Mail

time2 hours ago

  • Globe and Mail

Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management

BEIJING, July 21, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") ( a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the 3 rd China International Supply Chain Expo in Beijing. Leveraging its AI application services, innovative treatment solutions, and convenient pharmaceutical services, Fangzhou will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and obesity. Fangzhou and Novo Nordisk Signed Collaboration Memorandum Fangzhou's founder, chairman, and CEO Dr. Xie Fangmin, and Christine Zhou, Novo Nordisk Senior Vice President & President of Region China, attended the signing ceremony. By leveraging Novo Nordisk's expertise and innovative products in diabetes and obesity treatment, Fangzhou plans to employ its smart healthcare ecosystem and robust technology infrastructure to create a comprehensive health management service. This will include medication guidance, reminders, efficacy tracking, and health education, effectively shaping the value chain in the glucose control and weight loss sector. The aim is to shift the focus from a 'disease-centered' approach to a 'health-centered' model, providing patients with higher quality and more convenient one-stop healthcare services. Dr. Xie Fangmin remarked, 'We are partnering with Novo Nordisk, a leading global healthcare company, to explore AI technology and address the pain points of traditional health management. Together, we aim to deliver innovative digital solutions for managing blood sugar and weight on a global scale.' Christine Zhou said, 'With the combined strengths of both companies, this collaboration will closely integrate chronic disease prevention and digital innovation technology, jointly enhancing public awareness of diabetes and obesity. It will also support the aim that the concepts of early screening, early diagnosis, and early treatment are effectively implemented within smart healthcare environments.' Looking forward, both companies expect to explore further innovative collaborations in the medical industry's digital transformation, with the goal of benefiting patients with serious chronic diseases and accelerating the achievement of the 'Healthy China 2030' strategic objectives. About Fangzhou Inc. Fangzhou Inc. ( is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit

Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula

National Post

time3 hours ago

  • National Post

Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula

Article content Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile Article content IRVINE, Calif. — Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Article content Key Phase 2 Results Article content Primary Endpoint Achieved: Article content Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Article content Rapid Onset and Sustained Efficacy: Article content Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Article content Significant Symptom Relief: Article content Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Article content Excellent Safety Profile: Article content No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Article content Addressing a Significant Unmet Medical Need Article content Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Article content Study Design and Results Article content The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Article content 'There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use,' said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. 'The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life.' Article content 'As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004,' commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. 'The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula.' Article content About CBT-004 Article content CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Article content Next Steps and Regulatory Strategy Article content Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Article content Market Opportunity Article content The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. Article content About Cloudbreak Pharma Inc. Article content Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Article content Article content Article content Contacts Article content Contact Information: Article content Article content Cloudbreak Pharma Inc. Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store